Although NST has traditionally been used for patients with locally advanced breast cancer, it has become a routine practice due to increased rates of pathologic complete response (pCR), especially among those with triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.